tbuckley/cabot-search huggingface dataset:
TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL
Authors: Aaron Mochizuki, Alexander Lee, Joey Orpilla, Jenny Kienzler, Mildred Galvez, Frances Chow, Tom Davidson, Anthony Wang, Richard Everson, Linda Liau, Timothy Cloughesy, Robert Prins
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a dismal prognosis. Neoadjuvant anti-PD-1 blockade has demonstrated efficacy in melanoma, non-small cell lung cancer and recurrent GBM; however, responses vary. While T cells have garnered considerable attention in the context of immunotherapy, the role of myeloid cells in the GBM microenvironment remains controversial. METHODS We isolated CD45+ immune populations from patients who underwent brain tumor resection at UCLA. We hypothesized that myeloid cells in glioblastoma contribute to T cell dysfunction; however, this immune suppression can be mitigated by neoadjuvant PD-1 inhibition. To test this, we utilized mass cytometry and single-cell RNA sequencing to characterize these immune populations. RESULTS Mass cytometry profiling of tumor infiltrating lymphocytes from patients with GBM demonstrated a preponderance of CD11b+ myeloid populations (75% versus 25% CD3+). At the transcriptomic level, myeloid cells in newly diagnosed GBMs exhibited decreased expression of CCL4 (loge fold change -1.18, Bonferroni-adjusted P = 1.62x10-254) and its ligands compared to anaplastic astrocytoma. In ranked gene set enrichment analysis, patients who received neoadjuvant pembrolizumab demonstrated enrichment in TNFα-, NFκB- and lipid metabolism-related gene sets by bootstrapped Kolmogorov-Smirnov test (Benjamini-Hochberg adjusted P = 4.74x10-3, 1.45x10-2 and 2.48x10-3, respectively) in tumor-associated myeloid populations. Additionally, single-cell trajectory analysis demonstrated increased CCL4 and decreased ISG15 with neoadjuvant checkpoint inhibition. CONCLUSIONS Here, we utilize mass cytometry and single-cell RNA sequencing to demonstrate the predominance and transcriptomic features of myeloid populations in GBM. Myeloid cells in patients who receive neoadjuvant PD-1 blockade re-express increased levels NFκB, TNFα and CCL4, a cytokine crucial for the recruitment of dendritic cells to the tumor for antigen-specific T cell activation. By delving into the GBM microenvironment at the single-cell level, we hope to better delineate the role of myeloid populations in this uniformly fatal tumor.
Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy
Authors: Kevin A. David, Melissa Pulitzer, Joan Guitart, Maria Estela Martinez-Escala, Shamir Geller, Yaqun Wang, N. Nora Bennani, Kay M. Ristow, Daniel J. Landsburg, Nicole Winchell, Paul Haun, Pamela Allen, Basem M. William, Nathan Denlinger, Neha Mehta-Shah, Ryan A. Wilcox, Alexandra Hristov, Tatyana A. Feldman, Alex Weller, Andrew M. Evens, Steven M. Horwitz
Journal: Blood (2019)
Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma
Authors: Jun W. Kim, Cesar P. Marquez, Kaja Kostyrko, Amanda L. Koehne, Kieren Marini, David R. Simpson, Alex G. Lee, Stanley G. Leung, Leanne C. Sayles, Joseph Shrager, Irene Ferrer, Luis Paz-Ares, Melanie Hayden Gephart, Silvestre Vicent, Jennifer R. Cochran, E. Alejandro Sweet-Cordero
Journal: Nature Medicine (2019)
Looking Beyond Mortality Among Older Adults Who Are Frail and Considering Surgical Intervention
Authors: Adam Shellito, Marcia M. Russell, Ronnie A. Rosenthal
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard
Authors: Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani
Journal: Clinical and Molecular Hepatology (2019)

Background/Aims The American Association for the Study of Liver Diseases recommends ultrasound (US) screening for hepatocellular carcinoma (HCC) among cirrhotic patients, regardless of body mass index (BMI), every 6 months. We examined US sensitivity for diagnosis of HCC in obese patients. Methods Liver transplant patients data with HCC in explant was used (January 2012-December 2017). All patients underwent liver US within 3 months of diagnosis of HCC. Number/size of HCC lesions were extracted from radiologic and pathologic reports. Obesity was defined as BMI ≥30 kg/m2. Results One hundred sixteen patients were included. 80% were male, with mean BMI of 31 kg/m2. The most common underlying liver disease was hepatitis C virus (62%). At the time of diagnosis, median number of HCC lesions was 2 (interquartile range [IQR], 1–3), and median size of the largest lesion was 2.5 cm (IQR, 1.75–3.9). Overall sensitivity of US study for detection of HCC was 33% (95% confidence interval [CI], 29–48%). Sensitivity was 77% (95% CI, 62–93%) in patients with BMI<30 and 21% (95% CI, 11–30%) in patients with BMI≥30 (P<0.001). Size of the largest HCC lesion (P=0.290) and number of lesions (P=0.505) were not different between groups. Computed tomography (CT) scan detected HCC in 98% of the obese patients with negative US. Conclusions Sensitivity of US for detection of HCC is significantly lower among obese patients compared to overweight and normal weight patients. These patients may benefit from alternating between US and a different imaging modality. Keywords: Liver cirrhosis; Neoplasms; Obesity
Infection and Poliomyelitis
Authors: J. H. C. Clarke
Journal: BMJ (1954)

cardinal sign.Otherwise how can one account for the amount ot research on diagnosis which is still going on, and is still being published in the medical press of the world ?However, if we are to standardize treatment, let us also standardize the diagnosis withiout the awkward nautical feat of stressing cardinal points, while remembering-with vomiting-inter alia the work of Paladini' in diagnosis: " Malaria diagnosis by contraction of the muscles of the face during abdominal palpation."-Iam, etc., Dublin.
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR
Authors: Matthew J. Wieduwilt, Wendy Stock, Anjali S. Advani, Selina M. Luger, Richard A. Larson, Martin S. Tallman, Frederick R. Appelbaum, Mei-Jie Zhang, Khalid Bo-Subait, Brenda M. Sandmaier, Marcos de Lima, Partow Kebriaei, Mark Litzow, Wael Saber, Daniel J. Weisdorf
Journal: Blood (2019)
Alternative Donor and Disease-Specific Conditioning Regimen Hematopoietic Stem Cell Transplantation for Inherited Bone Marrow Failure Syndromes
Authors: Fang Xu, Min Xiong, Ruijuan Sun, Yanli Zhao, Jianping Zhang, Xingyu Cao, Deyan Liu, Zhijie Wei, Jiarui Zhou, Yue Lu, Peihua Lu, Daopei Lu
Journal: Blood (2019)
High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Hematopoietic and Microglia Recovery and Disease Correction in a Mouse Model of Hurler Syndrome
Authors: Kevin A. Goncalves, Sharon L. Hyzy, Melissa L. Brooks, Hans J. Hertzler, Anthony E. Boitano, Michael P. Cooke
Journal: Blood (2019)
TMIC-26. PRECLINICAL MODEL SYSTEMS OF GLIOBLASTOMA REVEAL MICROENVIRONMENTAL PROGRAMS AND DEPENDENCIES IN PATIENT TUMORS
Authors: Nicholas Bayley, Christopher Tse, Lynn Baufeld, Laura Gosa, Weihong Yan, Henan Zhu, Nikolas Balanis, Timothy Cloughesy, Linda Liau, Thomas Graeber, David Nathanson
Journal: Neuro-Oncology (2019)

Abstract Patient-derived model systems serve as a platform for translational research representing the heterogeneity of human cancers, and their success in recapitulating disease-driving genomic alterations is well-documented. While recent studies have demonstrated genomic and functional divergence in patient-derived models with passaging, the need for accurate preclinical models remains. Glioblastoma (GBM) is the most common and aggressive primary brain tumor, and thus far preclinical models have failed to consistently replicate the responses found in patients. We therefore aimed to evaluate the multi-omic fidelity of low-passage GBM model systems across in vitro and in vivo environments and to elucidate the molecular features in which they differ. To this end we established a biobank of glioma direct-from-patient orthotopic xenograft (GliomaPDOX) models and primary gliomasphere cultures (GSCs) and performed whole-exome and RNA sequencing of over 40 purified patient tumors and their matched GliomaPDOXs and GSCs to facilitate paired comparisons across a gradient of full tumor microenvironment (TME) presence. We observed global genomic and transcriptomic fidelity in both systems, but specific programmatic gene expression differences associated with cell-cell interactions in the brain TME, glial cell identity, and in vitro GSC-forming ability. GSCs and GSC-forming ability are strongly associated with an astrocytic gene expression signature, while more stem-like and oligodendrocytic patient tumors including IDH- and H3F3A-mutant GBMs more successfully engraft in GliomaPDOXs. This result implicates the brain TME as a support system for these more stem/oligo-like tumors. Transcription factor network analysis identified regulators of the NOTCH and MYC pathways as strongly enriched in this subgroup of patient tumors and their derivative xenografts, and provides potential targets for therapeutic intervention in near future experiments. Collectively, these findings underline the critical role of the TME in defining GBM cell state, reveal the heterogeneity of TME dependence across patient tumors, and link this dependency to therapeutically actionable molecular features.
INNV-26. IN VITRO CHEMO RESISTANCE PROFILES OF CIRCULATING GLIAL CELLS REPLICATE CHEMO CHARACTERISTICS OF TUMOR TISSUE
Authors: Dadasaheb Akolkar, Sanket Patil, Vishakha Mhase, Pradip Devhare, Pooja Fulmali, Revati Patil, Ajay Srinivasan, Vineet Datta, Stefan Schuster, Jatinder Bhatia, Rajan Datar
Journal: Neuro-Oncology (2019)

Abstract Survival of high-grade glioma patients remains dismal due to onset of resistance to even the limited systemic treatment option currently available. Except for indirect prediction of alkylating agent Temozolomide response through MGMT promotor methylation and NTRK fusions for larotrectinib, there are no biomarkers available for drug response prediction. Cell based, in vitro chemosensitivity assays can interrogate the efficacy of an array of cytotoxic drugs. However, the unavailability of live tumor cells for such assays pose challenges in clinical practice. Repeat biopsies are neither advisable nor feasible. Access to Circulating Glial Cells (CGCs) can provide real time insight into the chemo dynamics of the tumor. In this study, we show for the first time that CGCs can be harvested from peripheral blood of glioma patients for chemo response and resistance profiles (CRR) of cytotoxic drugs. CGCs were harvested from 15 ml of peripheral blood from high grade GBM patients (n=9) out of whom cells derived from surgically excised tumor tissue were also available for comparison in 2 patients. CellWizard™ process was adopted for enrichment of CGCs which is based upon epigenetically active media with paradoxical chemo-toxicity that selectively induces lethality in normal cells. This paradoxical cytotoxicity of the medium leads to selective elimination of most leukocytes thus facilitating a label free negative enrichment of CGCs. In vitro chemo sensitivity assay performed on live CGCs and cell death events were determined to evaluate response to different class of chemotherapy drugs. Evaluation of drug response showed very high concordance between tumor derived cells and CGCs in both patients where live tissue was available. In 7 patients where CGCs alone could be evaluated, the response showed replication between in vitro profile compared to treatment antecedents in 5 patients. 2 patients were treatment naïve and the response reflected high sensitivity to Temozolomide.
Abstract AP05: OVARIAN CANCER-ASSOCIATED RAD51D MUTATIONS WHICH IMPAIR ITS INTERACTION WITH XRCC2 RESULT IN DNA REPAIR DEFICIENCY
Authors: Robert A. Baldock, Catherine A. Pressimone, Jared M. Baird, Anton Y. Khodakov, Yoav Karpenshif, Edwige B. Garcin, Stéphanie Gon, Mauro Modesti, Kara A. Bernstein
Journal: Clinical Cancer Research (2019)

Abstract The proficiency of ovarian cancer cells to repair DNA double-strand breaks (DSBs) by homologous recombination (HR) is a key determinant in predicting response to targeted therapies such as PARP inhibitors (PARPi). The RAD51 paralogs act downstream of BRCA1/2 to facilitate HR. Numerous epidemiological studies have linked mutations in the RAD51 paralogs with hereditary ovarian cancer predisposition. Despite their substantial links to cancer predisposition and development, RAD51 paralog function during HR has remained elusive, in part due to limitations in studying recombination events downstream of RAD51 filament formation. Here we investigate the impact of cancer-associated mutations in the RAD51 paralog, RAD51D, using yeast 2/3-hybrid assays to screen for altered protein-protein interactions. Following the identification of mutations that disrupt the interaction between RAD51D and XRCC2 in yeast, we validated the interaction by co-immunoprecipitation in human cells. Importantly, we determined the impact of these mutations on HR-proficiency using a direct-repeat recombination assay. By characterizing the impact of cancer-associated mutations in the RAD51 paralogs on HR-proficiency, we aim to develop more effective predictive models for therapeutic sensitivity and resistance in patients who harbor similar mutations in these essential genes. Citation Format: Robert A. Baldock, Catherine A. Pressimone, Jared M. Baird, Anton Y. Khodakov, Yoav Karpenshif, Edwige B. Garcin, Stéphanie Gon, Mauro Modesti, Kara A. Bernstein. OVARIAN CANCER-ASSOCIATED RAD51D MUTATIONS WHICH IMPAIR ITS INTERACTION WITH XRCC2 RESULT IN DNA REPAIR DEFICIENCY [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr AP05.
The Effect of Chronic Viral Hepatitis on Serum Ferritin Level in Thalassemia Patients
Authors: Natthapat Rujeerapaiboon, Adisak Tantiworawit, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada, Pimlak Charoenkwan
Journal: Blood (2019)
EXTH-35. LASER INTERSTITIAL THERMAL THERAPY INCREASES BLOOD-BRAIN BARRIER AND BLOOD-TUMOR BARRIER PERMEABILITY IN A MOUSE MODEL OF GLIOBLASTOMA
Authors: Mounica Paturu, Afshin Salehi, Matthew Caine, Tatenda Mahlokozera, Hiroko Yano, Eric Leuthardt, Robyn Klein, Robert Schmidt, Albert Kim
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION A central challenge in glioblastoma treatment is the presence of the blood-brain barrier (BBB) and blood-tumor barrier (BTB), which prevent access of drugs to the brain and tumor respectively. Recent evidence in patients suggests laser interstitial thermal therapy (LITT), used clinically for tumor ablation, locally disrupts BBB integrity, potentially creating a therapeutic window to deliver otherwise brain-impermeant agents. METHODS A mouse model for LITT, established using a Nd-YAG laser coupled to a 600 mm fiber optic and thermocouple probe, was inserted via burrhole to target the somatosensory cortex. Syngeneic GL261 tumor cells were stereotactically implanted prior to LITT. BBB and BTB permeability were assessed through measurement of fluorescein and doxorubicin after IV injection. Permeability of IV dextran (10 and 70 kDa) and human IgG was monitored by immunohistochemistry (IHC) analysis. Mechanisms of BBB breakdown in vivo were explored utilizing electron microscopy and IHC. RESULTS By fluorescein assay, LITT-induced BBB and BTB permeability began one day post-treatment and was sustained for at least 2 weeks. Additionally, both normal brain and brain tumors demonstrated an increase in Dextran 10 kDa, Dextran 70 kDa, and human IgG extravasation after IV injection in vivo. Mechanistically, we provide evidence that LITT triggers both a decrease in tight junction integrity and an increase in brain endothelial cell transcytosis. As proof-of-concept that LITT can enhance tumor delivery of systemic drugs, LITT increased IV doxorubicin permeability in brain in vivo. Moreover, LITT plus doxorubicin significantly increased survival in brain tumor-bearing mice compared to doxorubicin or LITT alone. CONCLUSIONS Our data suggest that LITT increases BBB and BTB permeability over a defined time window to large molecular weight agents, including antibodies, through multiple cellular mechanisms. Our preclinical results with LITT plus doxorubicin, which mirror a current clinical trial, indicate LITT can enhance the efficacy of systemically delivered drugs.
Evaluation of Markers of Intravascular Hemolysis and Endothelial Dysfunction in Sickle Cell Anemia Patients with and without Hydroxyurea Therapy
Authors: Francine Chenou, Bidossessi Wilfried Hounkpe, Igor de Farias Domingos, Thais Helena Chaves Batista, Rodrigo Marcionilo Santana, Aderson da Silva Araujo, Marcos Andre Cavalcanti Bezerra, Fernando Ferreira Costa, Maria de Fátima Sonati, Erich V De Paula, Magnun Nueldo Nunes Santos
Journal: Blood (2019)
IMMU-38. CRISPR BASED GENOME EDITING OF HUMAN T CELLS TO TARGET H3.3K27M MUTATION IN GLIOMAS
Authors: Bindu Hegde, Theodore Roth, David Nguyen, Zinal Chheda, Ryan Apathy, Alex Marson, Hideho Okada
Journal: Neuro-Oncology (2019)

Abstract We recently identified an HLA-A*02:01-restricted CD8 T cell epitope encompassing the H3.3K27M mutation, which is common in diffuse midline glioma, and a corresponding high-affinity T cell receptor (TCR) that recognizes the epitope. While recombinant viral vectors have been widely used for genetic reprogramming of T cells, viral vectors are far from ideal as they typically integrate randomly into the genome and are not governed by the molecular regulatory mechanisms of the cell. We used a non-viral, CRISPR-Cas9-based approach to replace the endogenous TCR with H3.3K27M TCR at the TCR a constant region (TRAC) in human T cells. Co-electroporation of healthy donor-derived T cells with homology-directed repair (HDR) templates encoding the full-length sequence of H3.3K27M TCR along with CRISPR-Cas9 ribonucleoprotein (RNP) resulted in the integration of the new TCR into the TRAC locus by HDR. Antibody staining of TCR α/β and H3.3K27M dextramer showed replacement of endogenous TCR with H.3.3K27M TCR in ~5–10% of TCR+ CD8 T cells. Modifying the HDR template to include a binding site for Cas9, which contains the nuclear localization signal that acts as a “shuttle”, further enhanced the integration efficiency (~15% of TCR+ CD8 T cells). Furthermore, HLA-A2+ H3.3K27M TCR-engineered T cells selectively killed U87 glioma cells expressing the H3.3K27M epitope. In addition, the engineered T cells exhibited a stem memory-like phenotype when expanded in the presence of a cocktail of IL-2, IL-7 and IL-15. Taken together, these data provide evidence for non-viral genome editing as a strategy to engineer T cells with specific TCR for cancer immunotherapy.
Eltrombopag Improves Erythroid Differentiation in a Human iPSC Model of Diamond Blackfan Anemia
Authors: Husam Qanash, Kaari Linask, Jeanette Beers, Keyvan Keyvanfar, Sara Young-Baird, Waleed Hakami, Richard H. Smith, Jizhong Zou, Andre Larochelle
Journal: Blood (2019)
Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase
Authors: Minke A.E. Rab, Brigitte A. van Oirschot, Stephanie van Straaten, Bart J. Biemond, Jennifer Bos, Penelope A. Kosinski, Charles Kung, Eduard J. van Beers, Richard van Wijk
Journal: Blood (2019)
Socially Excluded Persons in Ireland Have an Increased Annual Risk of Hospitalisation Due to Venous Thromboembolic Disease
Authors: Karl Ewins, Fionnuala Ni Ainle, Eoghan Dunlea, Sarah Kelliher, Vicky Sandys, Hannorah Rooney, Lily Macken, Ni Cheallaigh Cliona
Journal: Blood (2019)
Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells
Authors: Liang Lin, Shih-Feng Cho, Kenneth Wen, Tengteng Yu, Phillip A Hsieh, Yuyin Li, Gang An, Lugui Qiu, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2019)
Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy
Authors: Daisuke Ogiya, Lisa Müller, Sigitas J Verselis, Heiner Schaal, Ivane Abiatari, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, Linda M. Pilarski, Teru Hideshima, Kenneth C. Anderson, Sophia Adamia
Journal: Blood (2019)
Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey
Authors: Fatma Keklik Karadag, Mustafa Nuri Yenerel, Yılmaz Mehmet, Hava uskudar Teke, Vildan Ozkocaman, Tulin Tuglular, Fuat Erdem, Ali Unal, Orhan Ayyildiz, Gulsum Ozet, Melda Ozkan, Emin Kaya, Mesut Ayer, Ozan Salim, Birol Güvenç, Hakan Ozdogu, Özgür Mehtap, Mehmet Sönmez, Nil Güler, Sibel Kabukcu Hacioglu, Ismet Aydogdu, Ozlen Bektas, Selami Kocak Toprak, Lale Kaynar, Munci Yagci, Salih Aksu, Anil Tombak, Volkan Karakus, Irfan Yavasoglu, Birgül Öneç, Mehmet Ali Özcan, Levent Ündar, Rıdvan Ali, Celalettin Ustun, Osman Ilhan, Guray Saydam, Fahri Sahin
Journal: Blood (2019)
Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen
Authors: Katerina Pavenski, Paul Knoebl, Marie Scully, Johanna A. Kremer Hovinga, Paul Coppo, Flora Peyvandi, Spero Cataland, Ara Metjian, Javier De La Rubia, Hilde De Winter, Rui de Passos Sousa, Filip Callewaert
Journal: Blood (2019)
Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis
Authors: Nathaniel Rosko, Hanjie Mo, Joslyn Rudoni, Caitlin Siebenaller, Sarah S Lee, Rajshekar Chakraborty, Beth M. Faiman, Jack Khouri, Alex V. Mejia Garcia, Christy J. Samaras, Faiz Anwer, Jason Valent
Journal: Blood (2019)
Treatment of Acute Malaria with Pyrimethamine
Authors: T. Wilson, J. F. B. Edeson
Journal: BMJ (1953)

BRITISH 253 and pulse rate 124.Procaine amide, 1 g., was injected intra- venously.Within five minutes the blood pressure became 65 and pulse fell to 90.The bleeding stopped.The operatioA was con- tinued uneventfully, there being only three swabs used, and the sucker was discontinued completely once the blood pressure had fallen to 65 mm.The blood pressure gradually rose to 75 mm.after 70 minutes, but no further bleeding occurred.The pulse was 92.On levelling, the blood pressure rose to 100 mm.Hg.Recovery was uneventful.